Noida Chronicle

Nephrosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market | Companies-Astellas Pharmaceuticals, Alexion Pharmaceuticals

 Breaking News
  • No posts were found

Nephrosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market | Companies-Astellas Pharmaceuticals, Alexion Pharmaceuticals

April 11
20:21 2023
Nephrosclerosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market | Companies-Astellas Pharmaceuticals, Alexion Pharmaceuticals
DelveInsight Business Research LLP
DelveInsight’s “Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Nephrosclerosis, historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s Nephrosclerosis Market Insights, Epidemiology, and Market Forecast-2032  report delivers an in-depth understanding of the Nephrosclerosis, historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Nephrosclerosis market report provides current treatment practices, emerging drugs, Nephrosclerosis market share of the individual therapies, and current and forecasted Nephrosclerosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Nephrosclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Nephrosclerosis market.

Some of the Key Facts of the Nephrosclerosis Market Report:

  • An estimated 2.7% of U.S. adults had Nephrosclerosis in the past year. Past year prevalence of Nephrosclerosis among adults was higher for females (3.8%) than for males (1.6%).

Nephrosclerosis Overview

Nephrosclerosis means the hardening of the kidney. In the United States and Europe, the terms hypertensive nephrosclerosis, benign nephrosclerosis, and nephroangiosclerosis are commonly used to describe the same clinical condition. Nephrosclerosis is the hardening of the walls of the small arteries and arterioles (small arteries that convey blood from arteries to the even smaller capillaries) of the kidney. This condition is caused by hypertension (high blood pressure).

 

Nephrosclerosis Epidemiology Insights

  • More than 20% of patients with systemic hypertension have chronic renal insufficiency.

  • The prevalence of hypertensive nephropathy among those with hypertension is 24.6%.

  • According to USRDS annual data report”USRDS”., the overall prevalence of CKD among patients over 65 years in 2017 was 14.5% (186,997 from 1,291,640), however in the hypertensive population aged 65+ years, it was 16.3%. 

  • The incidence of hemodialysis, peritoneal dialysis, and transplantation among CKD due to hypertension in the US population was reported to be 35,843 from 124,369 in 2017. Whereas the prevalence of these therapeutic modalities was 192,907 from 743,624.

Nephrosclerosis Epidemiology Segmentation

  • Nephrosclerosis Diagnosed cases 

  • Nephrosclerosis Treatment cases 

  • Nephrosclerosis Incident cases 

  • Nephrosclerosis Prevalent cases 

Nephrosclerosis Market Outlook 

The Nephrosclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Nephrosclerosis market trends by analyzing the impact of current Nephrosclerosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Nephrosclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Nephrosclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Nephrosclerosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Nephrosclerosis Market Trends

 Nephrosclerosis Key Companies 

 

  • Astellas Pharmaceuticals 

  • Alexion Pharmaceuticals 

  • And many others 

 Nephrosclerosis Therapies

  • TRK-100STP high dose

  • Beraprost

  • And many others 

 Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Nephrosclerosis  

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Nephrosclerosis Emerging Therapies

  9.  Nephrosclerosis  Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Market Drivers 

  12.  Market Barriers 

  13.  Appendix

  14.  Nephrosclerosis  Report Methodology

  15.  DelveInsight Capabilities

  16.  Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles